Literature DB >> 23344526

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

P Storti1, M Bolzoni, G Donofrio, I Airoldi, D Guasco, D Toscani, E Martella, M Lazzaretti, C Mancini, L Agnelli, K Patrene, S Maïga, V Franceschi, S Colla, J Anderson, A Neri, M Amiot, F Aversa, G David Roodman, N Giuliani.   

Abstract

Hypoxia-inducible transcription factor-1 (HIF-1α) is overexpressed in multiple myeloma (MM) cells within the hypoxic microenvironment. Herein, we explored the effect of persistent HIF-1α inhibition by a lentivirus short hairpin RNA pool on MM cell growth either in vitro or in vivo and on the transcriptional and pro-angiogenic profiles of MM cells. HIF-1α suppression did not have a significant impact on MM cell proliferation and survival in vitro although, increased the antiproliferative effect of lenalidomide. On the other hand, we found that HIF-1α inhibition in MM cells downregulates the pro-angiogenic genes VEGF, IL8, IL10, CCL2, CCL5 and MMP9. Pro-osteoclastogenic cytokines were also inhibited, such as IL-7 and CCL3/MIP-1α. The effect of HIF-1α inhibition was assessed in vivo in nonobese diabetic/severe combined immunodeficiency mice both in a subcutaneous and an intratibial MM model. HIF-1α inhibition caused a dramatic reduction in the weight and volume of the tumor burden in both mouse models. Moreover, a significant reduction of the number of vessels and vascular endothelial growth factors (VEGFs) immunostaining was observed. Finally, in the intratibial experiments, HIF-1α inhibition significantly blocked bone destruction. Overall, our data indicate that HIF-1α suppression in MM cells significantly blocks MM-induced angiogenesis and reduces MM tumor burden and bone destruction in vivo, supporting HIF-1α as a potential therapeutic target in MM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23344526     DOI: 10.1038/leu.2013.24

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  54 in total

1.  The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Authors:  Paola Storti; Denise Toscani; Irma Airoldi; Valentina Marchica; Sophie Maiga; Marina Bolzoni; Elena Fiorini; Nicoletta Campanini; Eugenia Martella; Cristina Mancini; Daniela Guasco; Valentina Ferri; Gaetano Donofrio; Franco Aversa; Martine Amiot; Nicola Giuliani
Journal:  Haematologica       Date:  2015-12-11       Impact factor: 9.941

Review 2.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

3.  Hypoxia inducible factor-1 alpha and multiple myeloma.

Authors:  Archana Bhaskar; Bhupendra Nath Tiwary
Journal:  Int J Adv Res (Indore)       Date:  2016-01-01

4.  Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.

Authors:  Lavinia Raimondi; Angela De Luca; Nicola Amodio; Mauro Manno; Samuele Raccosta; Simona Taverna; Daniele Bellavia; Flores Naselli; Simona Fontana; Odessa Schillaci; Roberto Giardino; Milena Fini; Pierfrancesco Tassone; Alessandra Santoro; Giacomo De Leo; Gianluca Giavaresi; Riccardo Alessandro
Journal:  Oncotarget       Date:  2015-05-30

Review 5.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

6.  Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Authors:  Muhammad Zahoor; Marita Westhrin; Kristin Roseth Aass; Siv Helen Moen; Kristine Misund; Katarzyna Maria Psonka-Antonczyk; Mariaserena Giliberto; Glenn Buene; Anders Sundan; Anders Waage; Anne-Marit Sponaas; Therese Standal
Journal:  Blood Adv       Date:  2017-12-13

7.  Hypoxia-inducible KDM3A addiction in multiple myeloma.

Authors:  Sho Ikeda; Akihiro Kitadate; Fumito Abe; Naoto Takahashi; Hiroyuki Tagawa
Journal:  Blood Adv       Date:  2018-02-27

8.  Sema4D expression and secretion are increased by HIF-1α and inhibit osteogenesis in bone metastases of lung cancer.

Authors:  Wu-Gui Chen; Jing Sun; Wei-Wei Shen; Si-Zhen Yang; Ying Zhang; Xu Hu; Hao Qiu; Shang-Cheng Xu; Tong-Wei Chu
Journal:  Clin Exp Metastasis       Date:  2019-01-07       Impact factor: 5.150

9.  Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.

Authors:  Alberto L Horenstein; Valeria Quarona; Denise Toscani; Federica Costa; Antonella Chillemi; Vito Pistoia; Nicola Giuliani; Fabio Malavasi
Journal:  Mol Med       Date:  2016-10-13       Impact factor: 6.354

10.  Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms.

Authors:  Tijana Subotički; Olivera Mitrović Ajtić; Bojana B Beleslin-Čokić; Ronny Nienhold; Miloš Diklić; Dragoslava Djikić; Danijela Leković; Tanja Bulat; Dragana Marković; Mirjana Gotić; Constance T Noguchi; Alan N Schechter; Radek C Skoda; Vladan P Čokić
Journal:  Mol Carcinog       Date:  2016-07-08       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.